SHELTON, CT / ACCESS Newswire / May 8, 2025 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company") today reported that it has received approval from the National Ethics Committee for Health (CNES) of ...

Coronaviruses not only use the machinery of the human cells they infect: they modify them to achieve optimal conditions to ...

SHELTON, CT / ACCESSWIRE / November 14, 2023 / NanoViricides, Inc. (AMEX:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines ...

If researchers were able to activate innate immunity in people, they would be able to control infection in a wide range of viruses, inoculating many against their effects and making them less ...

SHELTON, CONNECTICUT / ACCESS Newswire / July 23, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the ...

(BOSTON) — About 30% of all respiratory tract infections are caused by coronaviruses, leading to widespread illnesses and, in some cases, to epidemic and even pandemic outbreaks, as we experienced ...

SHELTON, CT / ACCESS Newswire / July 21, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.: NNVC) (the “Company”), and a clinical stage, leading global pioneer in the development of ...

Clinical outcomes among adult inpatients were no worse when broad-spectrum antibiotic therapy was delayed vs started early, challenging the belief that overly broad-spectrum empiric antibiotic therapy ...